secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2023-11-20T23:59:59+00:00
Accession:  0000950170-23-065087
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta reports Q4 net loss $28.1M; initiates EDP-323 Phase 2a RSV study
-----------------------------------------------------------------------

- Q4 revenue $18.9M (down from $20.3M YoY); FY revenue $79.2M (down from $86.2M).
- Net loss $28.1M ($1.33/diluted share) vs $26.3M ($1.27) in Q4 2022; FY loss $133.8M ($6.38) vs $121.8M ($5.91).
- Cash and marketable securities $370M; expects to fund operations through fiscal 2027.
- FY2024 guidance: R&D $100-120M (down from $163.5M actual), G&A $45-50M (down from $52M).
- Initiated Phase 2a challenge study for RSV candidate EDP-323; data expected Q3 2024. Advancing EDP-938 Phase 2 trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000095017023065087/0000950170-23-065087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000095017023065087/enta-20231120.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-065087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer